United Europeans for development of pharmacogenomics in multiple sclerosis network

Koen Vandenbroeck, Manuel Comabella, Eva Tolosa, Robert Goertsches, David Brassat, Rogier Hintzen, Carmen Infante-Duarte, Alexander Favorov, Sergio Escorza, Ricardo Palacios, Jorge R. Oksenberg, Pablo Villoslada

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis (MS) is a chronic inflammatory, disabling disease of the CNS. A recent study has estimated the annual cost of MS in Europe at €12.5 billion. There is no definitive cure for the disease. Immunomodulatory therapies, such as IFN-β and glatiramer acetate, are only partially effective. Various new therapies in the final stages of clinical trials are being developed in the absence of efficacy biomarkers. Hence, there is a pressing need for identification of MS treatment response biomarkers. The focus of the multicenter research initiative United Europeans for the development of pharmacogenomics in MS (UEPHA*MS) is to promote and improve training opportunities in the novel supradisciplinary area of pharmacogenomics, biomarker research and systems biology applied to MS. UEPHA*MS is a Marie Curie Initial Training network funded by the 7th Framework Programme of the European Commission. The main scientific goals of this network are both to enhance our knowledge of the mechanisms determining response outcomes of existing immunomodulatory therapies and to identify novel therapeutic opportunities. UEPHA*MS is composed of 11 internationally recognized research teams from five countries with an assortment of expertise in complementary disciplines. The UEPHA*MS network will provide a coherent and internationally competitive platform for the training of young scientists based on multidisciplinary state-of-the-art laboratory-based and network-wide activities. This network will be instrumental in priming young scientists for Europe's collective effort toward improved provision of healthcare based on personalized medicine.

Original languageEnglish (US)
Pages (from-to)885-894
Number of pages10
JournalPharmacogenomics
Volume10
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Pharmacogenetics
Multiple Sclerosis
Immunomodulation
Biomarkers
Research
Precision Medicine
Systems Biology
Central Nervous System Diseases
Therapeutics
Clinical Trials
Delivery of Health Care
Costs and Cost Analysis

Keywords

  • Interferon
  • Multiple sclerosis
  • Pharmacogenomics
  • Proteomics
  • Systems biology
  • Training

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Vandenbroeck, K., Comabella, M., Tolosa, E., Goertsches, R., Brassat, D., Hintzen, R., ... Villoslada, P. (2009). United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics, 10(5), 885-894. https://doi.org/10.2217/pgs.09.33

United Europeans for development of pharmacogenomics in multiple sclerosis network. / Vandenbroeck, Koen; Comabella, Manuel; Tolosa, Eva; Goertsches, Robert; Brassat, David; Hintzen, Rogier; Infante-Duarte, Carmen; Favorov, Alexander; Escorza, Sergio; Palacios, Ricardo; Oksenberg, Jorge R.; Villoslada, Pablo.

In: Pharmacogenomics, Vol. 10, No. 5, 2009, p. 885-894.

Research output: Contribution to journalArticle

Vandenbroeck, K, Comabella, M, Tolosa, E, Goertsches, R, Brassat, D, Hintzen, R, Infante-Duarte, C, Favorov, A, Escorza, S, Palacios, R, Oksenberg, JR & Villoslada, P 2009, 'United Europeans for development of pharmacogenomics in multiple sclerosis network', Pharmacogenomics, vol. 10, no. 5, pp. 885-894. https://doi.org/10.2217/pgs.09.33
Vandenbroeck K, Comabella M, Tolosa E, Goertsches R, Brassat D, Hintzen R et al. United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics. 2009;10(5):885-894. https://doi.org/10.2217/pgs.09.33
Vandenbroeck, Koen ; Comabella, Manuel ; Tolosa, Eva ; Goertsches, Robert ; Brassat, David ; Hintzen, Rogier ; Infante-Duarte, Carmen ; Favorov, Alexander ; Escorza, Sergio ; Palacios, Ricardo ; Oksenberg, Jorge R. ; Villoslada, Pablo. / United Europeans for development of pharmacogenomics in multiple sclerosis network. In: Pharmacogenomics. 2009 ; Vol. 10, No. 5. pp. 885-894.
@article{8988d3a0f327435cbb4858a803b6274d,
title = "United Europeans for development of pharmacogenomics in multiple sclerosis network",
abstract = "Multiple sclerosis (MS) is a chronic inflammatory, disabling disease of the CNS. A recent study has estimated the annual cost of MS in Europe at €12.5 billion. There is no definitive cure for the disease. Immunomodulatory therapies, such as IFN-β and glatiramer acetate, are only partially effective. Various new therapies in the final stages of clinical trials are being developed in the absence of efficacy biomarkers. Hence, there is a pressing need for identification of MS treatment response biomarkers. The focus of the multicenter research initiative United Europeans for the development of pharmacogenomics in MS (UEPHA*MS) is to promote and improve training opportunities in the novel supradisciplinary area of pharmacogenomics, biomarker research and systems biology applied to MS. UEPHA*MS is a Marie Curie Initial Training network funded by the 7th Framework Programme of the European Commission. The main scientific goals of this network are both to enhance our knowledge of the mechanisms determining response outcomes of existing immunomodulatory therapies and to identify novel therapeutic opportunities. UEPHA*MS is composed of 11 internationally recognized research teams from five countries with an assortment of expertise in complementary disciplines. The UEPHA*MS network will provide a coherent and internationally competitive platform for the training of young scientists based on multidisciplinary state-of-the-art laboratory-based and network-wide activities. This network will be instrumental in priming young scientists for Europe's collective effort toward improved provision of healthcare based on personalized medicine.",
keywords = "Interferon, Multiple sclerosis, Pharmacogenomics, Proteomics, Systems biology, Training",
author = "Koen Vandenbroeck and Manuel Comabella and Eva Tolosa and Robert Goertsches and David Brassat and Rogier Hintzen and Carmen Infante-Duarte and Alexander Favorov and Sergio Escorza and Ricardo Palacios and Oksenberg, {Jorge R.} and Pablo Villoslada",
year = "2009",
doi = "10.2217/pgs.09.33",
language = "English (US)",
volume = "10",
pages = "885--894",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - United Europeans for development of pharmacogenomics in multiple sclerosis network

AU - Vandenbroeck, Koen

AU - Comabella, Manuel

AU - Tolosa, Eva

AU - Goertsches, Robert

AU - Brassat, David

AU - Hintzen, Rogier

AU - Infante-Duarte, Carmen

AU - Favorov, Alexander

AU - Escorza, Sergio

AU - Palacios, Ricardo

AU - Oksenberg, Jorge R.

AU - Villoslada, Pablo

PY - 2009

Y1 - 2009

N2 - Multiple sclerosis (MS) is a chronic inflammatory, disabling disease of the CNS. A recent study has estimated the annual cost of MS in Europe at €12.5 billion. There is no definitive cure for the disease. Immunomodulatory therapies, such as IFN-β and glatiramer acetate, are only partially effective. Various new therapies in the final stages of clinical trials are being developed in the absence of efficacy biomarkers. Hence, there is a pressing need for identification of MS treatment response biomarkers. The focus of the multicenter research initiative United Europeans for the development of pharmacogenomics in MS (UEPHA*MS) is to promote and improve training opportunities in the novel supradisciplinary area of pharmacogenomics, biomarker research and systems biology applied to MS. UEPHA*MS is a Marie Curie Initial Training network funded by the 7th Framework Programme of the European Commission. The main scientific goals of this network are both to enhance our knowledge of the mechanisms determining response outcomes of existing immunomodulatory therapies and to identify novel therapeutic opportunities. UEPHA*MS is composed of 11 internationally recognized research teams from five countries with an assortment of expertise in complementary disciplines. The UEPHA*MS network will provide a coherent and internationally competitive platform for the training of young scientists based on multidisciplinary state-of-the-art laboratory-based and network-wide activities. This network will be instrumental in priming young scientists for Europe's collective effort toward improved provision of healthcare based on personalized medicine.

AB - Multiple sclerosis (MS) is a chronic inflammatory, disabling disease of the CNS. A recent study has estimated the annual cost of MS in Europe at €12.5 billion. There is no definitive cure for the disease. Immunomodulatory therapies, such as IFN-β and glatiramer acetate, are only partially effective. Various new therapies in the final stages of clinical trials are being developed in the absence of efficacy biomarkers. Hence, there is a pressing need for identification of MS treatment response biomarkers. The focus of the multicenter research initiative United Europeans for the development of pharmacogenomics in MS (UEPHA*MS) is to promote and improve training opportunities in the novel supradisciplinary area of pharmacogenomics, biomarker research and systems biology applied to MS. UEPHA*MS is a Marie Curie Initial Training network funded by the 7th Framework Programme of the European Commission. The main scientific goals of this network are both to enhance our knowledge of the mechanisms determining response outcomes of existing immunomodulatory therapies and to identify novel therapeutic opportunities. UEPHA*MS is composed of 11 internationally recognized research teams from five countries with an assortment of expertise in complementary disciplines. The UEPHA*MS network will provide a coherent and internationally competitive platform for the training of young scientists based on multidisciplinary state-of-the-art laboratory-based and network-wide activities. This network will be instrumental in priming young scientists for Europe's collective effort toward improved provision of healthcare based on personalized medicine.

KW - Interferon

KW - Multiple sclerosis

KW - Pharmacogenomics

KW - Proteomics

KW - Systems biology

KW - Training

UR - http://www.scopus.com/inward/record.url?scp=66849106883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66849106883&partnerID=8YFLogxK

U2 - 10.2217/pgs.09.33

DO - 10.2217/pgs.09.33

M3 - Article

VL - 10

SP - 885

EP - 894

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 5

ER -